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Abstract: In this study, we aimed to clarify the expression profiles of Yes-associated protein (YAP) and phosphory-
lated YAP (pYAP) protein and to verify the clinical implication of the expression of YAP protein in human breast 
cancer. We selected 678 cases of formalin-fixed paraffin-embedded (FFPE) breast cancer tissue to construct tissue 
microarray (TMA) blocks. We performed immunohistochemical staining of estrogen receptor (ER), progesterone 
receptor (PR), human epidermal growth receptor-2 (HER-2) and Ki-67 and fluorescent in situ hybridization (FISH) 
assay for HER-2 on the TMA sections and divided breast cancers into molecular subtypes: luminal A, luminal B, 
HER-2, triple negative breast cancer (TNBC). Then, we examined YAP and pYAP expression status using immunohis-
tochemical analysis according to the molecular subtypes of breast cancer. We found that HER-2 type breast cancer 
demonstrated elevated expression level in tumoral cytoplasmic YAP (P = 0.011) and pYAP (P = 0.049). Expressions 
of stromal YAP (P = 0.002) and pYAP (P < 0.001) were higher in luminal B and HER-2 type breast cancer but lower in 
TNBC. In univariate analysis, nuclear YAP expression of tumor cells was associated with shorter overall survival (OS) 
(P = 0.024). Cytoplasmic YAP expression of HER-2 type breast cancer cells negatively affected disease-free survival 
(DFS) (P = 0.034). In conclusion, we concluded that there was a significant difference in YAP and pYAP expression 
status according to molecular subtypes and tumoral and cellular components of breast cancers. Finally, we found 
that nuclear and cytoplasmic YAP expression could be a prognostic marker for breast cancer patients.
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Introduction
Yes-Associated Protein (YAP) is a recently iden-
tified oncogenic transcription coactivator. As a 
causative oncogene found in the 11q22 ampli-
con that is frequently observed in human can-
cer, YAP enhances invasion and proliferation, 
suppresses apoptosis and is sufficient for 
transformation [1]. Finally, YAP is the down-
stream effector molecule of a newly emerging 
tumor suppressor pathway called the Hippo 
pathway [2]. Thus, understanding the function 
of YAP may provide insight to universally con-
served control mechanisms of tumorigenesis 
and tumor progression.
When YAP is phosphorylated on serine 127 by 
Lats kinase, phosphorylated YAP is seques-
tered from the nucleus by 14-3-3 and trans- 
cription activities of target genes are thus 
decreased [3]. In contrast, YAP overexpression, 
or nuclear localization of YAP, was frequently 
found in many cancers [4]. Recently, many 
researchers reported the functions of YAP in 
breast cancers, but these mechanisms still 
remain poorly understood. Several studies 
demonstrated YAP as a tumor suppressor in 
breast cancer, showing decreased level of YAP 
expression in human breast cancer tissue rela-
tive to normal breast tissue [5], increased cell 
migration and invasiveness of YAP-downre- 
gulated breast cancer cells in vitro, and 
increased tumor growth in the YAP-knockout 
mouse in vivo [6]. On the contrary, other 
researchers have asserted that YAP acts as an 
oncogene in breast cancer, demonstrating that 
YAP overexpression enhanced cellular prolifera-
tion [7], and xenograft mice transplanted with a 
YAP-overexpressing breast cancer cell line pro-
moted tumor formation and growth in compari-
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son to the control tumor group [8]. Therefore, it 
is necessary to clarify the expression status of 
YAP in human breast cancer tissue and its clini-
cal implications in breast cancer.
In this study, we compared YAP and phosphory-
lated YAP (pYAP) expression profiles in breast 
cancers according to their molecular subtypes 
and cellular compartments, and then evaluat-
ed YAP as a prognostic factor in breast cancer 
patients.
Materials and methods
Patient selection
Patients diagnosed with invasive breast cancer 
and treated by surgical resection during January 
2002 to December 2006 were included in this 
study. Patients who received preoperative neo-
adjuvant chemotherapy or hormonal treatment 
were excluded. This study was approved by the 
Institutional Review Board of Yonsei University 
Severance Hospital. A breast pathologist (Koo 
JS) retrospectively reviewed the histology of all 
cases using hematoxylin-eosin (H&E) stained 
slides. The histological grade was assessed 
using the Nottingham grading system [9]. 
Clinicopathologic parameters evaluated in 
each case included patient age at initial diag-
nosis, lymph node metastasis, tumor recur-
rence, distant metastasis, and patient sur- 
vival.
Tissue microarray
On H&E stained slides of tumors, a representa-
tive area was selected and the corresponding 
spot was marked on the surface of the paraffin 
block. Using a biopsy needle, the selected area 
was punched out and a 3-mm tissue core was 
placed into a 6 × 5 recipient block. Tissue from 
the invasive tumor was then extracted. Two tis-
sue cores were extracted to minimize extrac-
tion bias. Each tissue core was assigned a 
unique tissue microarray (TMA) location num-
ber that was linked to a database containing 
other clinicopathologic data.
Immunohistochemistry
The antibodies used for immunohistochemistry 
in this study are shown in Table 1. We per-
formed immunohistochemical staining on for-
malin-fixed paraffin-embedded (FFPE) tissue 
using TMA. Briefly, 5-μm-thick sections were 
obtained with a microtome, transferred onto 
adhesive slides, and dried at 62°C for 30 min-
utes. After incubation with primary antibodies 
(Table 1), immunodetection was performed 
with biotinylated antimouse immunoglobulin, 
followed by peroxidase-labeled streptavidin 
using a labeled streptavidin biotin kit with 
3,3’-diaminobenzidine chromogen as sub-
strate. The primary antibody incubation step 
was omitted in the negative control. Positive 
control tissue was used per manufacturer’s 
recommendation. Slides were counterstained 
with Harris hematoxylin.
Interpretation of immunohistochemical stain-
ing
All immunohistochemical markers were asse- 
ssed by light microscopy. A cut-off value of 1% 
or more positively stained nuclei was used to 
define estrogen receptor (ER) and progesterone 
receptor (PR) positivity [10]. Human epidermal 
growth receptor-2 (HER-2) staining was ana-
lyzed according to the American Society of 
Clinical Oncology (ASCO)/College of American 
Pathologists (CAP) guidelines using the follow-
ing categories: 0 = no immunostaining; 1+ = 
weak incomplete membranous staining, less 
than 10% of tumor cells; 2+ = complete mem-
branous staining, either uniform or weak in at 
least 10% of tumor cells; and 3+ = uniform 
intense membranous staining in at least 30% 
of tumor cells [11]. HER-2 immunostaining was 
considered positive when strong (3+) membra-
nous staining was observed whereas cases 
with 0 to 1+ were regarded as negative. Cases 
showing 2+ HER-2 expression were evaluated 
for HER-2 amplification by fluorescent in situ 
hybridization (FISH).
Expression status of YAP and pYAP in tumor 
cells and stromal cells was assessed according 
to the cellular compartments such as nucleus 
and cytoplasm. Immunostaining result was 
graded 0 (negative), 1 (weak), 2 (moderate), or 
3 (strong). We determined positive reactivity 
when moderate (grade 2) or strong (grade 3) 
positive cancer cells were identified over 10% 
of the tumor area.
Ki-67 labeling indices (LI) were scored by count-
ing the number of positively stained nuclei and 
expressed as a percentage of total tumor cells.
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Tumor phenotype classification
In this study, we classified breast cancer phe-
notypes according to the immunohistochemis-
try results for ER, PR, HER-2, and Ki-67 LI. FISH 
results for HER-2 were as follows [12]: luminal A 
type: ER and/or PR positive, HER-2 negative, 
and Ki-67 LI <14%; luminal B type: (HER-2 neg-
ative) ER and/or PR positive, HER-2 negative, 
and Ki-67 LI ≥14% and (HER-2 positive) ER 
and/or PR positive and HER-2 overexpressed 
and/or amplified; HER-2 type: ER and PR nega-
tive and HER-2 overexpressed and/or ampli-
fied; TNBC type: ER, PR, and HER-2 negative.
Statistical analysis
Data were analyzed using SPSS for Windows, 
Version 12.0 (SPSS Inc., Chicago, IL, USA). To 
determine statistical significance, Student’s t 
and Fisher’s exact tests were used for continu-
ous and categorical variables, respectively. 
Table 1. Source, clone, and dilution of antibodies used in this study
antibody Company clone dilution
YAP related
    YAP Santa Cruz Biotechnology, INC., California, USA 9A1 1:100
    Phosphate YAP (ser127) Abcam, Cambridge, UK EP1675Y 1:100
Molecular subtype related
    ER Thermo Scientific, San Siego, CA, USA SP1 1:100
    PR DAKO, Glostrup, Denmark PgR 1:50
    HER-2 DAKO, Glostrup, Denmark Polyclonal 1:1500
    Ki-67 Abcam, Cambridge, UK MIB 1:1000
Table 2. Clinicopathologic characteristics of patients according to breast cancer phenotype
Parameters Total  (N = 678) (%)
Luminal A  
(n = 280) (%)
Luminal B  
(n = 156) (%)
HER-2  
(n = 67) (%)
TNBC  
(n = 175) (%) P-value
Age (years) 0.022
    ≤50 403 (59.4) 160 (57.1) 105 (67.3) 31 (46.3) 107 (61.1)
    >50 275 (40.6) 120 (42.9) 51 (32.7) 36 (53.7) 68 (38.9)
Histologic grade <0.001
    I/II 453 (66.8) 253 (90.4) 106 (67.9) 35 (52.2) 59 (33.7)
    III 225 (33.2) 27 (9.6) 50 (32.1) 32 (47.8) 116 (66.3)
Tumor stage 0.014
    T1 323 (47.6) 149 (53.2) 77 (49.4) 31 (46.3) 66 (37.7)
    T2/T3 355 (52.4) 131 (46.8) 79 (50.6) 36 (53.7) 109 (62.3)
Nodal metastasis 0.163
    Absent 400 (59.0) 158 (56.4) 86 (55.1) 41 (61.2) 115 (65.7)
    Present 278 (41.0) 122 (43.6) 70 (44.9) 26 (38.8) 60 (34.3)
Estrogen receptor status <0.001
    Negative 252 (37.2) 5 (1.8) 5 (3.2) 67 (100.0) 175 (100.0)
    Positive 426 (62.8) 275 (98.2) 151 (96.8) 0 (0.0) 0 (0.0)
Progesterone receptor status <0.001
    Negative 336 (49.6) 46 (16.4) 48 (30.8) 67 (100.0) 175 (100.0)
    Positive 342 (50.4) 234 (83.6) 108 (69.2) 0 (0.0) 0 (0.0)
HER-2 status <0.001
    Negative 531 (78.3) 280 (100.0) 76 (48.7) 0 (0.0) 175 (100.0)
    Positive 147 (21.7) 0 (0.0) 80 (51.3) 67 (100.0) 0 (0.0)
Ki-67 LI (%) <0.001
    ≤14 380 (56.0) 280 (100.0) 46 (29.5) 27 (40.3) 27 (15.4)
    >14 298 (44.0) 0 (0.0) 110 (70.5) 40 (59.7) 148 (84.6)
Tumor recurrence 60 (8.8) 15 (5.4) 13 (8.3) 9 (13.4) 23 (13.1) 0.018
Patients’ death 58 (8.6) 13 (4.6) 13 (8.3) 9 (13.4) 23 (13.1) 0.007
Duration of clinical follow-up (months, mean ± SD) 70 ± 31 72 ± 29 70 ± 31 66 ± 35 67 ± 33 0.390
TNBC, triple negative breast cancer.
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Statistical significance was reached when P < 
0.05. Kaplan-Meier survival curves and log-
rank statistics were employed to evaluate time 
to tumor recurrence and overall survival. 
Multivariate regression analysis was performed 
using the Cox proportional hazards model.
Results
Patients’ clinicopathologic characteristics
First, we investigated clinical features of breast 
cancer patients from the medical records and 
reviewed pathologic features of patients’ breast 
cancer tissue (Table 2). In total, included cases 
of breast cancers were 280 cases of luminal A 
type (41.3%), 156 cases of luminal B type 
(23.0%), 67 cases of HER-2 type (9.9%), and 
175 cases of triple negative breast cancer 
(TNBC) type (25.8%). TNBC-type breast cancers 
demonstrated higher histologic grade (P < 
0.001), higher T stage (P = 0.014), and higher 
Ki-67 LI (P < 0.001) than other molecular sub-
types. HER-2 type breast cancer was associat-
ed with older age at diagnosis (P = 0.022), more 
frequent tumor recurrence (P = 0.018) and 
lower survival rate (P = 0.007) than other 
molecular subtypes.
Expression of YAP and pYAP according to mo-
lecular subtypes of breast cancer
Next, we performed immunohistochemical 
staining for identification of YAP and pYAP 
expression status according to the molecular 
subtype of breast cancer (Table 3 and Figure 
1). We further evaluated expression profiles of 
YAP and pYAP dividing cellular components into 
the nucleus and cytoplasm. Our results showed 
increased tumoral cytoplasmic YAP expression 
(P = 0.011) and tumoral cytoplasmic pYAP 
expression (P = 0.049) in HER-2 type breast 
cancer tissue compared to other molecular 
subtypes. In stromal component, YAP (P = 
0.002) and pYAP (P < 0.001) were increased in 
luminal B and HER-2 type breast cancer tissues 
but relatively decreased in TNBC type breast 
cancer tissue. However, there was no signifi-
cant difference in nuclear YAP expression 
according to the molecular subtype of breast 
cancer.
Correlation between expression of YAP and 
pYAP proteins and clinicopathologic factors
We investigated various clinicopathologic 
parameters known to affect patients’ prognosis 
according to expression status of YAP and pYAP: 
Table 3. Expression of YAP and pYAP according to breast cancer phenotype
Parameters Total (N = 678) (%)
Luminal A
(n = 280) (%)
Luminal B
(n = 156) (%)
HER-2
(n = 67) (%)
TNBC
(n = 175) (%) P-value
YAP (T-Nu) 0.181
    Negative 636 (93.8) 261 (93.2) 152 (97.4) 62 (92.5) 161 (92.0)
    Positive 42 (6.2) 19 (6.8) 4 (2.6) 5 (7.5) 14 (8.0)
YAP (T-Cy) 0.011
    Negative 646 (95.3) 265 (94.6) 151 (96.8) 59 (88.1) 171 (97.7)
    Positive 32 (4.7) 15 (5.4) 5 (3.2) 8 (11.9) 4 (2.3)
YAP (S) 0.002
    Negative 574 (84.7) 246 (87.9) 121 (77.6) 51 (76.1) 156 (89.1)
    Positive 104 (15.3) 34 (12.1) 35 (22.4) 16 (23.9) 19 (10.9)
pYAP (T-Cy) 0.049
    Negative 541 (79.8) 224 (80.0) 129 (82.7) 45 (67.2) 143 (81.7)
    Positive 137 (20.2) 56 (20.0) 27 (17.3) 22 (32.8) 32 (18.3)
pYAP (T-Nu) 0.449
    Negative 672 (99.1) 279 (99.6) 155 (99.4) 66 (98.5) 172 (98.3)
    Positive 6 (0.9) 1 (0.4) 1 (0.6) 1 (1.5) 3 (1.7)
pYAP (S) <0.001
    Negative 615 (90.7) 261 (93.2) 129 (82.7) 57 (85.1) 168 (96.0)
    Positive 63 (9.3) 19 (6.8) 27 (17.3) 10 (14.9) 7 (4.0)
TNBC, triple negative breast cancer.
YAP in breast cancer
3228 Int J Clin Exp Pathol 2014;7(6):3224-3234
Figure 1. Expression of YAP and pYAP according to the molecular subtype of breast cancer. HER-2 type breast can-
cer demonstrated cytoplasmic YAP and pYAP in cancer cells. Luminal B and HER-2 type breast cancer revealed a 
higher expression rate of stromal YAP and pYAP, but TNBC did not. Microscopic magnification, 200X.
age at diagnosis, tumor stage, nodal metasta-
sis, histologic grade, ER status, PR status, 
HER-2 status, and Ki-67 L.I. (Tables 4 and 5). 
Both YAP expression (P = 0.001) and pYAP 
expression (P = 0.001) were increased in the 
stromal cells of HER-2 type breast cancer. 
Cytoplasmic pYAP expression was associated 
lower tumor stage (P = 0.003). However, nucle-
ar YAP expression in tumor cells was not associ-
ated with any significant differences in various 
clinicopathologic parameters.
Impact of expression of YAP and pYAP proteins 
on patient prognosis
We analyzed overall survival (OS) rate and dis-
ease-free survival (DFS) rate of breast cancer 
patients according to YAP and pYAP expression 
using Kaplan-Meier survival curve (Figure 2). 
Distinctively, patients with breast cancer who 
showed nuclear YAP expression in tumor cells 
had inferior OS compared to patients with 
nuclear YAP-negative breast cancer (Figure 2A, 
P = 0.024). When we analyzed OS and DFS 
according to the molecular subtype of breast 
cancer, cytoplasmic YAP expression of tumor 
cells in HER-2 type negatively affected DFS of 
breast cancer patients (Figure 2B, P = 0.034). 
However, nuclear YAP expression of tumor cells 
did not affect either OS or DFS in each molecu-
lar subtype of breast cancer.
Next, we investigated predictable variables 
associated with patients’ survival according to 
YAP expression status using Cox regression 
analysis (Table 6). In univariate analysis, only 
nuclear YAP expression of tumor cells was cor-
related with shorter OS (P = 0.024) and demon-
strated a tendency of negative correlation with 
DFS (P = 0.079).
When the predictable parameters were adjust-
ed for by multivariate analysis (Table 7), a ten-
dency for nuclear YAP expression of tumor cells 
to independently affect inferior OS was revealed 
(Hazard ratio: 2.073, 95% CI: 0.973-4.416, P = 
0.059). As expected, lymph node metastasis 
was associated with shorter DFS (Hazard ratio: 
2.210, 95% CI: 1.295-3.771, P = 0.004) and 
shorter OS (Hazard ratio: 1.879, 95% CI: 1.098-
3.216, P = 0.021). Higher tumor stage was also 
associated with shorter DFS (Hazard ratio: 
2.024, 95% CI: 1.109-3.693, P = 0.022). 
Discussion
We investigated the expression profiles of YAP 
and pYAP in various molecular subtypes of 
breast cancers. Previous studies have reported 
the expression frequency of YAP in breast can-
cer to range from 45-75%, which is much higher 
than our results showing 6.2% of tumors having 
nuclear expression and 4.7% of tumors having 
YAP in breast cancer
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Table 4. Correlations between the expression of YAP and clinicopathologic parameters
Parameters
YAP (T-Nu) YAP (T-Cy) YAP (S)
Negative
n = 636 (%)
Positive
n = 42 (%) P-value
* Negative
n = 646 (%)
Positive
n = 32 (%) P-value
* Negative
n = 574 (%)
Positive
n = 104 (%) P-value
*
Age (years) 0.737 0.138 0.046
    ≤50 377 (59.3) 26 (61.9) 388 (60.1) 15 (46.9) 332 (57.8) 71 (68.3)
    >50 259 (40.7) 16 (38.1) 258 (39.9) 17 (53.1) 242 (42.2) 33 (31.7)
Histologic grade 0.512 0.812 0.908
    I/II 423 (66.5) 30 (71.4) 431 (66.7) 22 (68.8) 383 (66.7) 70 (67.3)
    III 213 (33.5) 12 (28.6) 215 (33.3) 10 (31.2) 191 (33.3) 34 (32.7)
Tumor stage 0.522 0.784 0.756
    T1 305 (48.0) 18 (42.9) 307 (47.5) 16 (50.0) 272 (47.4) 51 (49.0)
    T2/T3 331 (52.0) 24 (57.1) 339 (52.5) 16 (50.0) 302 (52.6) 53 (51.0)
Nodal metastasis 0.564 0.435 0.938
    Absent 377 (59.3) 23 (54.8) 379 (58.7) 21 (65.6) 339 (59.1) 61 (58.7)
    Present 259 (40.7) 19 (45.2) 267 (41.3) 11 (34.4) 235 (40.9) 43 (41.3)
Estrogen receptor status 0.264 0.678 0.715
    Negative 233 (36.6) 19 (45.2) 239 (37.0) 13 (40.6) 215 (37.5) 37 (35.6)
    Positive 403 (63.4) 23 (54.8) 407 (63.0) 19 (59.4) 359 (62.5) 67 (64.4)
Progesterone receptor status 0.706 0.959 0.743
    Negative 314 (49.4) 22 (52.4) 320 (49.5) 16 (50.0) 286 (49.8) 50 (48.1)
    Positive 322 (50.6) 20 (47.6) 326 (50.5) 16 (50.0) 288 (50.2) 54 (51.9)
HER-2 status 0.230 0.074 0.001
    Negative 495 (77.8) 36 (85.7) 510 (78.9) 21 (65.6) 462 (80.5) 69 (66.3)
    Positive 141 (22.2) 6 (14.3) 136 (21.1) 11 (34.4) 112 (19.5) 35 (33.7)
Ki-67 LI (%) 0.639 0.138 0.177
    ≤14 355 (55.8) 25 (59.5) 358 (55.4) 22 (68.8) 328 (57.1) 52 (50.0)
    >14 281 (44.2) 17 (40.5) 288 (44.6) 10 (31.2) 246 (42.9) 52 (50.0)
*P-value was corrected by the Bonferroni method.
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Table 5. Correlations between the expression of pYAP and clinicopathologic parameters
Parameters
pYAP (T-Cy) pYAP (T-Nu) pYAP (S)
Negative
n = 541 (%)
Positive
n = 137 (%) P-value
* Negative
n = 672 (%)
Positive
n = 6 (%) P-value
* Negative
n = 615 (%)
Positive
n = 63 (%) P-value
*
Age (years) 0.066 0.691 0.882
    ≤50 331 (61.2) 72 (52.6) 400 (59.5) 3 (50.0) 365 (59.3) 38 (60.3)
    >50 210 (38.8) 65 (47.4) 272 (40.5) 3 (50.0) 250 (40.7) 25 (39.7)
Histologic grade 0.755 0.994 0.087
    I/II 363 (67.1) 90 (65.7) 449 (66.8) 4 (66.7) 417 (67.8) 36 (57.1)
    III 178 (32.9) 47 (34.3) 223 (33.2) 2 (33.3) 198 (32.2) 27 (42.9)
Tumor stage 0.003 0.688 0.113
    T1 242 (44.7) 81 (59.1) 321 (47.8) 2 (33.3) 287 (46.7) 36 (57.1)
    T2/T3 299 (55.3) 56 (40.9) 351 (52.2) 4 (66.7) 328 (53.3) 27 (42.9)
Nodal metastasis 0.723 1.000 0.753
    Absent 321 (59.3) 79 (57.7) 396 (58.9) 4 (66.7) 364 (59.2) 36 (57.1)
    Present 220 (40.7) 58 (42.3) 276 (41.1) 2 (33.3) 251 (40.8) 27 (42.9)
Estrogen receptor status 0.161 0.202 0.227
    Negative 194 (35.9) 58 (42.3) 248 (36.9) 4 (66.7) 233 (37.9) 19 (30.2)
    Positive 347 (64.1) 79 (57.7) 424 (63.1) 2 (33.3) 382 (62.1) 44 (69.8)
Progesterone receptor status 0.864 0.447 0.264
    Negative 269 (49.7) 67 (48.9) 332 (49.4) 4 (66.7) 309 (50.2) 27 (42.9)
    Positive 272 (50.3) 70 (51.1) 340 (50.6) 2 (33.3) 306 (49.8) 36 (57.1)
HER-2 status 0.090 1.000 0.001
    Negative 431 (79.7) 100 (73.0) 526 (78.3) 5 (83.3) 492 (80.0) 39 (61.9)
    Positive 110 (20.3) 37 (27.0) 146 (21.7) 1 (16.7) 123 (20.0) 24 (38.1)
Ki-67 LI (%) 0.815 0.413 0.251
    ≤14 302 (55.8) 78 (56.9) 378 (56.2) 2 (33.3) 349 (56.7) 31 (49.2)
    >14 239 (44.2) 59 (43.1) 294 (43.8) 4 (66.7) 266 (43.3) 32 (50.8)
*P-value was corrected by the Bonferroni method.
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cytoplasmic expression [5, 8]. We believe that 
this difference may be explained by the cut-off 
value of positive reactivity. In this study, we 
determined positive reactivity of YAP protein 
when moderately (grade 2) or strongly (grade 3) 
positive cancer cells were identified over 10% 
of tumor area, because normal luminal cells or 
myoepithelial cells also had weak positivity of 
YAP protein. Based on the same criteria, a pre-
vious report indicated that 62% of breast can-
cers had moderate positivity and only 6% had 
strong positivity [13]; and in another study, 29% 
of breast cancers demonstrated YAP [8].
As YAP protein functions as a transcription 
coactivator in the nucleus and phosphorylated 
YAP protein is sequestered in the cytoplasm, it 
is needed to localize YAP and pYAP protein to 
identify the oncogenic function of YAP in breast 
cancer cells. We divided cellular components 
such as the nucleus and cytoplasm and sorted 
through the expression status of YAP and pYAP 
in each component using immunohistochemi-
cal assay. Our results showed that the expres-
sion of YAP protein differed between each 
molecular subtype of breast cancer. We discov-
ered that HER-2 type breast cancer demon-
strated increased expression level of cytoplas-
mic YAP and pYAP among subtypes, although 
previous studies reported that YAP expression 
of breast cancer cells was associated with inva-
sive lobular carcinoma [14] and ER/PR positivi-
ty [5]. As we mentioned above, YAP protein is 
phosphorylated in the cytoplasm by a kinase 
cascade associated with the Hippo signaling 
pathway. Because HER-2 is a transmembrane 
receptor which has an intrinsic tyrosine kinase 
[15], we suggest that cytoplasmic overexpres-
sion of YAP and pYAP, but not nuclear overex-
pression, in HER-2 type breast cancer could be 
due to the possibility that HER-2 amplification/
overexpression increases intrinsic kinase activ-
ity and, thus, a significant amount of YAP pro-
tein can be phosphorylated in the cytoplasm. 
However, the precise mechanism of increased 
phosphorylation of YAP in HER-2 type breast 
cancer should be studied further. Unexpectedly, 
the nuclear pYAP expression in a few cases of 
breast cancer ranged from 0.4 to 1.7% accord-
ing to molecular subtype. This result may be 
due to non-specific or over staining and nuclear 
pYAP expression may not, in fact, be associated 
with any clinicopathologic features of breast 
cancer.
This is the first study to focus on the stromal 
expression of YAP and pYAP proteins in breast 
cancer. YAP and pYAP expression of stromal 
cells were increased in luminal B type and 
HER-2 type breast cancers but decreased in 
TNBC. We struggled to understand this phe-
nomenon and considered the possibility of 
Figure 2. Survival analysis of breast cancer patients according to the expression status of YAP protein. A. Overall sur-
vival curve according to the nuclear expression status of YAP in breast cancer cells. B. Disease-free survival curve 
according to the cytoplasmic expression status of YAP in HER-2 type breast cancer cells. T-Nu, nuclear expression of 
tumor cells. T-Cy, cytoplasmic expression of tumor cells.
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mechanotransduction of tumor cells in sur-
rounding stromal cells regulated by the Hippo 
signaling pathway. It is known that the actin 
cytoskeleton could decrease the phosphoryla-
tion of YAP as a key molecule of the Hippo sig-
naling pathway and de-phosphorylated YAP is 
translocated into the nucleus, increasing tran-
scripts of downstream growth factors such as 
CCN1/CYR61 and CCN2/CTGF [16, 17]. In 
breast cancer, the concept of cancer associat-
ed fibroblasts consisting of tumor stroma is 
explained by several types of cells with a well-
known component being the myofibroblast in 
which α-smooth muscle actin is expressed 
Table 6. Univariate analysis of the impact of the expression of YAP and pYAP in breast cancers on 
disease-free survival or overall survival by log-rank test
Parameters Number of patients/recurrence/death 
Disease-free survival Overall survival
Mean survival (95% CI) 
months P-value
Mean survival (95% CI) 
months P-value
YAP (T-Nu) 0.079 0.024
    Negative 636/53/50 126 (123-130) 130 (127-133)
    Positive 42/7/8 111 (99-123) 116 (103-130)
YAP (T-Cy) 0.579 0.924
    Negative 646/56/55 127 (124-130) 129 (126-132)
    Positive 32/4/3 117 (105-129) 124 (115-134)
YAP (S) 0.163 0.110
    Negative 574/55/54 124 (120-128) 128 (125-131)
    Positive 104/5/4 132 (126-138) 134 (130-139)
pYAP (T-Cy) 0.920 0.894
    Negative 541/49/47 127 (123-130) 129 (126-132)
    Positive 137/11/11 117 (110-124) 127 (120-134)
pYAP (T-Nu) n/a n/a
    Negative 672/60/58 n/a n/a
    Positive 6/0/0 n/a n/a
pYAP (S) 0.981 0.894
    Negative 615/55/53 126 (122-130) 129 (126-132)
    Positive 63/5/5 98 (92-103) 121 (114-128)
Table 7. Multivariate analysis of breast-cancer survival
Included parameters
Disease-free survival Overall survival
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
T stage 0.022 0.100
    T1 versus T2-3 2.024 1.109-3.693 1.629 0.910-2.914
N stage 0.004 0.021
    N0 versus N1-3 2.210 1.295-3.771 1.879 1.098-3.216
Histologic grade 0.507 0.726
    I/II versus III 1.213 0.686-2.144 0.900 0.500-1.621
ER status 0.291 0.223
    Negative versus Positive 1.496 0.709-3.158 1.575 0.758-3.272
PR status 0.274 0.086
    Negative versus Positive 1.534 0.713-3.300 1.976 0.909-4.296
HER-2 status 0.531 0.618
    Negative versus Positive 1.208 0.669-2.183 1.164 0.640-2.115
YAP (T-Nu) 0.125 0.059
    Negative versus Positive 1.867 0.841-4.147 2.073 0.973-4.416
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[18]. To sum up these findings, we believe that 
YAP and pYAP expression of tumor stromal cells 
composed of cancer-associated fibroblasts 
may be affected by cancer cells.
In this study, we investigated the prognosis of 
patients with nuclear YAP-expressing breast 
cancer. When the survival analysis included all 
subtypes of breast cancer, nuclear YAP expres-
sion of the cancer cells was associated with 
inferior OS. A detailed analysis of molecular 
subtypes showed cytoplasmic YAP expression 
of tumor cells in HER-2 type breast cancer was 
related to shorter DFS. In the same manner, 
previous studies have suggested that YAP 
expression is associated with poor prognosis in 
various solid tumors including ovarian cancer 
[19], urinary bladder cancer [20], colorectal 
cancer [21], esophageal cancer [22], stomach 
cancer [23], and lung cancer [24]. In breast 
cancer, it has been thought that YAP was not an 
independent prognostic marker [13]. Accor- 
dingly, we also did not consider YAP expression 
to be an independent predictable parameter in 
Cox multivariate analysis. Although only one 
report has demonstrated that decreased levels 
of YAP expression in luminal A type breast can-
cer was associated with decreased DFS [25], it 
is necessary to verify the effect of YAP expres-
sion of each molecular subtype on patients’ 
prognosis.
To conclude, YAP and pYAP proteins were 
expressed differently according to the molecu-
lar subtypes of breast cancer and its cellular 
components. In this study, we show that 
increased nuclear YAP expression correlated 
with decreased OS in breast cancer and overex-
pression of cytoplasmic YAP in HER-2 type 
breast cancer was associated with shorter 
DFS. 
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